FibroBiologics, Inc. (FBLG)
Nasdaq: FBLG · Pharmaceutical Preparations · Houston, TX · filing with the SEC since 2023
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
| Report filed | Feb 24, 2026 | Mar 31, 2025 | Feb 29, 2024 | · |
| Research and development | 7,407 | 4,504 | 2,368 | 1,147 |
| General and administrative | 9,242 | 9,233 | 6,521 | 3,320 |
| Total operating expenses | 16,649 | 13,737 | 8,889 | 4,467 |
| Operating income | -16,649 | -13,737 | -8,889 | -4,467 |
| Interest expense | 204 | 20 | 147 | 265 |
| Interest and investment income | 247 | 251 | · | · |
| Other income (expense), net | -619 | 32 | -213 | · |
| Total non-operating income (expense) | -1,997 | 2,576 | -213 | · |
| Income tax expense | 0 | 0 | 0 | 0 |
| Net income | -18,646 | -11,161 | -16,485 | -5,121 |
| Net income to common shareholders | · | -11,161 | -19,058 | -5,121 |
| Earnings per share, basic | -0.42 | -0.34 | -0.68 | -0.18 |
| Earnings per share, diluted | -0.42 | -0.34 | -0.68 | -0.18 |
| Weighted average shares, basic | 44,660,518 | 32,875,075 | 28,230,842 | 28,230,842 |
| Weighted average shares, diluted | 44,660,518 | 32,875,075 | 28,230,842 | 28,230,842 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Research and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseDebt
us-gaap:InterestExpenseInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding